The O
magnitude O
of O
the O
relative O
risk O
associated O
with O
a O
rare O
HRAS1 O
allele O
was O
not O
altered O
by O
adjusting O
for O
the O
other O
known O
risk O
factors O
for O
hereditary B
ovarian I
cancer I
( O
5 O
) O
. O

To O
determine O
the O
molecular O
basis O
of O
Type B
II I
deficiency I
the O
two O
Type O
II O
C2Q0 O
genes O
were O
isolated O
and O
transfected O
separately O
into O
L O
- O
cells O
. O

A O
second O
, O
recently O
identified O
familial B
breast I
cancer I
gene O
, O
BRCA2 O
( O
refs O
5 O
- O
8 O
) O
, O
accounts O
for O
a O
proportion O
of O
breast B
cancer I
roughly O
equal O
to O
BRCA1 O
. O

Here O
we O
investigate O
the O
rate O
of O
BRCA2 O
mutation O
in O
sporadic B
breast I
cancers I
and O
in O
a O
set O
of O
cell O
lines O
that O
represent O
twelve O
other O
tumour B
types O
. O

The O
present O
study O
confirms O
the O
involvement O
of O
BRCA1 O
in O
disease O
predisposition O
for O
a O
subset O
of O
hereditary B
breast I
cancer I
families O
often O
characterized O
by O
ovarian B
cancers I
. O

Canavan B
disease I
is O
inherited O
as O
an O
autosomal O
recessive O
trait O
that O
is O
caused O
by O
the O
deficiency B
of I
aspartoacylase I
( O
ASPA O
) O
. O

In O
vitro O
expression O
of O
mutant O
cDNA O
clones O
demonstrated O
that O
all O
of O
these O
mutations O
led O
to O
a O
deficiency B
of I
ASPA I
and O
should O
therefore O
result O
in O
Canavan B
disease I
. O
. O

Identification O
and O
chromosomal O
localization O
of O
Atm O
, O
the O
mouse O
homolog O
of O
the O
ataxia B
- I
telangiectasia I
gene O
. O

Atm O
, O
the O
mouse O
homolog O
of O
the O
human O
ATM O
gene O
defective O
in O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
, O
has O
been O
identified O
. O

Atm O
, O
the O
mouse O
homolog O
of O
the O
human O
ATM O
gene O
defective O
in O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
, O
has O
been O
identified O
. O

This O
localization O
makes O
Wasp O
a O
candidate O
for O
involvement O
in O
scurfy O
, O
a O
T O
cell O
- O
mediated O
fatal B
lymphoreticular I
disease I
of O
mice O
that O
has O
previously O
been O
proposed O
as O
a O
mouse O
homolog O
of O
Wiskott B
- I
Aldrich I
syndrome I
. O

Colchicine O
in O
breast O
milk O
of O
patients O
with O
familial B
Mediterranean I
fever I
. O

To O
clarify O
whether O
colchicine O
is O
excreted O
in O
breast O
milk O
, O
and O
to O
compare O
its O
concentrations O
in O
the O
serum O
and O
breast O
milk O
of O
lactating O
women O
who O
have O
familial B
Mediterranean I
fever I
( O
FMF B
) O
. O

However O
, O
both O
models O
lack O
other O
frequent O
DM B
symptoms O
including O
the O
fibre O
- O
type O
dependent O
atrophy B
, O
myotonia B
, O
cataract B
and O
male B
- I
infertility I
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
an O
autosomal B
dominant I
disorder I
resulting O
from O
the O
expansion O
of O
a O
CTG O
repeat O
in O
the O
3 O
untranslated O
region O
of O
a O
putative O
protein O
kinase O
( O
DMPK O
) O
. O

Dmpk O
- O
/ O
- O
mice O
develop O
a O
late O
- O
onset O
, O
progressive B
skeletal I
myopathy I
that O
shares O
some O
pathological O
features O
with O
DM B
. O

Increased O
coronary B
heart I
disease I
in O
Japanese O
- O
American O
men O
with O
mutation O
in O
the O
cholesteryl O
ester O
transfer O
protein O
gene O
despite O
increased O
HDL O
levels O
. O

Plasma O
high O
density O
lipoprotein O
( O
HDL O
) O
levels O
are O
strongly O
genetically O
determined O
and O
show O
a O
general O
inverse O
relationship O
with O
coronary B
heart I
disease I
( O
CHD B
) O
. O

Aniridia B
in O
man O
and O
Small O
eye O
in O
mice O
are O
semidominant B
developmental I
disorders I
caused O
by O
mutations O
within O
the O
paired O
box O
gene O
PAX6 O
. O

This O
question O
is O
of O
particular O
interest O
for O
the O
human O
enzyme O
galactose O
- O
l O
- O
phosphate O
uridylyl O
- O
transferase O
( O
GALT O
) O
, O
impairment O
of O
which O
results O
in O
the O
inherited B
metabolic I
disorder I
galactosemia B
, O
because O
many O
if O
not O
most O
patients O
studied O
to O
date O
are O
compound O
heterozygotes O
rather O
than O
true O
molecular O
homozygotes O
. O

Germline O
VHL B
gene O
mutations O
predispose O
to O
the O
development O
of O
retinal B
, I
cerebellar I
and I
spinal I
haemangioblastomas I
, O
renal B
cell I
carcinoma I
and O
phaeochromocytoma B
. O

Genetic O
heterogeneity O
in O
hereditary B
breast I
cancer I
: O
role O
of O
BRCA1 O
and O
BRCA2 O
. O

However O
, O
it O
is O
not O
yet O
clear O
what O
proportion O
of O
hereditary B
breast I
cancer I
is O
explained O
by O
BRCA1 O
and O
BRCA2 O
or O
by O
some O
other O
unidentified O
susceptibility O
gene O
( O
s O
) O
. O

We O
describe O
the O
proportion O
of O
hereditary B
breast I
cancer I
explained O
by O
BRCA1 O
or O
BRCA2 O
in O
a O
sample O
of O
North O
American O
hereditary B
breast I
cancers I
and O
assess O
the O
evidence O
for O
additional O
susceptibility O
genes O
that O
may O
confer O
hereditary B
breast I
or I
ovarian I
cancer I
risk O
. O

We O
describe O
the O
proportion O
of O
hereditary B
breast I
cancer I
explained O
by O
BRCA1 O
or O
BRCA2 O
in O
a O
sample O
of O
North O
American O
hereditary B
breast I
cancers I
and O
assess O
the O
evidence O
for O
additional O
susceptibility O
genes O
that O
may O
confer O
hereditary B
breast I
or I
ovarian I
cancer I
risk O
. O

BRCA1 O
and O
BRCA2 O
probably O
explain O
the O
majority O
of O
hereditary B
breast I
cancer I
that O
exists O
in O
the O
North O
American O
population O
. O

However O
, O
one O
or O
more O
additional O
genes O
may O
yet O
be O
found O
that O
explain O
some O
proportion O
of O
hereditary B
breast I
cancer I
. O
. O

An O
intronic O
mutation O
in O
a O
lariat O
branchpoint O
sequence O
is O
a O
direct O
cause O
of O
an O
inherited B
human I
disorder I
( O
fish B
- I
eye I
disease I
) O
. O

Mutations O
associated O
with O
variant O
phenotypes O
in O
ataxia B
- I
telangiectasia I
. O

We O
have O
identified O
14 O
families O
with O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
in O
which O
mutation O
of O
the O
ATM O
gene O
is O
associated O
with O
a O
less O
severe O
clinical O
and O
cellular O
phenotype O
( O
approximately O
10 O
% O
- O
15 O
% O
of O
A B
- I
T I
families O
identified O
in O
the O
United O
Kingdom O
) O
. O

We O
have O
identified O
14 O
families O
with O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
in O
which O
mutation O
of O
the O
ATM O
gene O
is O
associated O
with O
a O
less O
severe O
clinical O
and O
cellular O
phenotype O
( O
approximately O
10 O
% O
- O
15 O
% O
of O
A B
- I
T I
families O
identified O
in O
the O
United O
Kingdom O
) O
. O

We O
have O
identified O
14 O
families O
with O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
in O
which O
mutation O
of O
the O
ATM O
gene O
is O
associated O
with O
a O
less O
severe O
clinical O
and O
cellular O
phenotype O
( O
approximately O
10 O
% O
- O
15 O
% O
of O
A B
- I
T I
families O
identified O
in O
the O
United O
Kingdom O
) O
. O

The O
second O
A B
- I
T I
allele O
has O
a O
different O
mutation O
in O
each O
patient O
. O

Mutations O
detected O
in O
two O
of O
four O
of O
these O
are O
missense O
mutations O
, O
normally O
rare O
in O
A B
- I
T I
patients O
. O

The O
demonstration O
of O
mutations O
giving O
rise O
to O
a O
slightly O
milder O
phenotype O
in O
A B
- I
T I
raises O
the O
interesting O
question O
of O
what O
range O
of O
phenotypes O
might O
occur O
in O
individuals O
in O
whom O
both O
mutations O
are O
milder O
. O

Chromosome O
3p O
deletion O
was O
detected O
in O
98 O
per O
cent O
of O
non B
- I
papillary I
renal I
cell I
carcinomas I
and O
in O
25 O
per O
cent O
of O
chromophobe O
renal B
cell I
carcinomas I
. O

No O
mobility O
shift O
was O
seen O
in O
any O
of O
the O
23 O
chromophobe O
renal B
cell I
carcinomas I
. O

Comparative O
genome O
mapping O
of O
the O
ataxia B
- I
telangiectasia I
region O
in O
mouse O
, O
rat O
, O
and O
Syrian O
hamster O
. O

Chromosomal O
locations O
of O
the O
Atm O
( O
ataxia B
- I
telangiectasia I
( O
AT B
) O
- O
mutated O
) O
and O
Acat1 O
( O
mitochondrial O
acetoacetyl O
- O
CoA O
thiolase O
) O
genes O
in O
mouse O
, O
rat O
, O
and O
Syrian O
hamster O
were O
determined O
by O
direct O
R O
- O
banding O
FISH O
. O

Pediatric B
alveolar I
rhabdomyosarcoma I
is O
characterized O
by O
a O
chromosomal O
translocation O
that O
fuses O
parts O
of O
the O
PAX3 O
and O
FKHR O
genes O
. O

A O
2 O
year O
old O
female O
presenting O
with O
bilateral B
sporadic I
aniridia I
was O
found O
to O
have O
an O
apparently O
balanced O
reciprocal O
translocation O
with O
a O
chromosome O
11 O
breakpoint O
within O
band O
p13 O
. O

Classical O
phenylketonuria B
( O
PKU B
) O
is O
an O
autosomal B
recessive I
disorder I
caused O
by O
a O
deficiency B
of I
hepatic I
phenylalanine I
hydroxylase I
( O
PAH O
) O
. O

Vectors O
derived O
from O
a O
recombinant O
retrovirus O
or O
a O
DNA O
/ O
protein O
complex O
can O
efficiently O
transduce O
the O
PAH O
cDNA O
into O
PAH B
- I
deficient I
hepatocytes O
in O
vitro O
, O
but O
the O
application O
of O
these O
vector O
systems O
is O
presently O
limited O
by O
their O
low O
transduction O
efficiency O
in O
vivo O
. O

In O
contrast O
, O
a O
vector O
derived O
from O
a O
recombinant O
adenovirus O
can O
restore O
10 O
% O
- O
80 O
% O
of O
normal O
hepatic O
PAH O
activity O
into O
PAH B
- I
deficient I
mice O
, O
which O
completely O
normalizes O
serum O
phenylalanine O
levels O
. O

BRCA1 O
and O
BRCA2 O
are O
the O
two O
major O
identified O
causes O
of O
inherited B
breast I
cancer I
, O
with O
mutations O
in O
either O
gene O
conferring O
up O
to O
80 O
- O
90 O
% O
lifetime O
risk O
of O
breast B
cancer I
in O
carrier O
females O
. O

Mutations O
in O
BRCA1 O
account O
for O
approximately O
45 O
% O
of O
familial B
breast I
cancer I
and O
90 O
% O
of O
inherited B
breast I
/ I
ovarian I
cancer I
, O
whereas O
mutations O
in O
BRCA2 O
account O
for O
a O
comparable O
percentage O
of O
inherited B
breast I
cancer I
cases O
. O

Mutations O
in O
BRCA1 O
account O
for O
approximately O
45 O
% O
of O
familial B
breast I
cancer I
and O
90 O
% O
of O
inherited B
breast I
/ I
ovarian I
cancer I
, O
whereas O
mutations O
in O
BRCA2 O
account O
for O
a O
comparable O
percentage O
of O
inherited B
breast I
cancer I
cases O
. O

The O
6174delT O
mutation O
in O
BRCA2 O
was O
recently O
identified O
as O
a O
frequent O
mutation O
in O
8 O
out O
of O
107 O
Ashkenazi O
Jewish O
women O
diagnosed O
with O
breast B
cancer I
by O
age O
50 O
( O
ref O
. O
8 O
) O
, O
as O
well O
as O
in O
three O
Ashkenazi O
male B
breast I
cancer I
patients O
. O

This O
expanded O
population O
- O
based O
study O
confirms O
that O
the O
BRCA1 O
185delAG O
mutation O
and O
the O
BRCA2 O
6174delT O
mutation O
constitute O
the O
two O
most O
frequent O
mutation O
alleles O
predisposing O
to O
hereditary B
breast I
cancer I
among O
the O
Ashkenazim O
, O
and O
suggests O
a O
relatively O
lower O
penetrance O
for O
the O
6174delT O
mutation O
in O
BRCA2 O

The O
gene O
mutated O
in O
ataxia B
- I
telangiectasia I
( O
AT B
) O
patients O
, O
denoted O
ATM O
, O
encodes O
a O
putative O
protein O
or O
lipid O
kinase O
. O

ATM O
, O
the O
gene O
mutated O
in O
the O
inherited B
human I
disease I
ataxia B
- I
telangiectasia I
, O
is O
a O
member O
of O
a O
family O
of O
kinases O
involved O
in O
DNA O
metabolism O
and O
cell O
- O
cycle O
checkpoint O
control O
. O

ATM O
, O
the O
gene O
mutated O
in O
the O
inherited B
human I
disease I
ataxia B
- I
telangiectasia I
, O
is O
a O
member O
of O
a O
family O
of O
kinases O
involved O
in O
DNA O
metabolism O
and O
cell O
- O
cycle O
checkpoint O
control O
. O

Initial O
evaluation O
of O
the O
ATM O
knockout O
animals O
indicates O
that O
inactivation O
of O
the O
mouse O
ATM O
gene O
recreates O
much O
of O
the O
phenotype O
of O
ataxia B
- I
telangiectasia I
. O

Where O
it O
is O
combined O
with O
a O
C6 B
- I
deficient I
gene O
, O
the O
serum O
C7 O
levels O
can O
be O
surprisingly O
high O
, O
possibly O
because O
there O
is O
no O
C6 O
generating O
C56 O
to O
consume O
the O
C7 O
. O

Genetic O
bases O
of O
human O
complement B
C7 I
deficiency I
. O

Complement B
C7 I
deficiency I
( O
C7D B
) O
is O
associated O
frequently O
with O
recurrent O
bacterial B
infections I
, O
especially O
meningitis B
caused O
by O
Neisseria B
meningitidis I
. O

HPRT B
- I
deficient I
mice O
generated O
using O
mouse O
embryonic O
stem O
cells O
exhibit O
none O
of O
the O
behavioral O
symptoms O
associated O
with O
the O
Lesch B
- I
Nyhan I
syndrome I
. O

Administration O
of O
drugs O
that O
inhibit O
adenine O
phosphoribosyltransferase O
( O
APRT O
) O
in O
HPRT B
- I
deficient I
mice O
has O
produced O
the O
suggestion O
that O
deficiency B
of I
APRT I
in O
combination O
with O
HPRT B
- I
deficiency I
in O
mice O
may O
lead O
to O
self O
- O
mutilation O
behavior O
[ O
C O
. O
L O
. O
Wu O
and O
D O
. O
W O
. O
Melton O
( O
1993 O
) O
Nature O
Genet O
. O
3 O
, O
235 O
- O
240 O
] O
. O

Administration O
of O
drugs O
that O
inhibit O
adenine O
phosphoribosyltransferase O
( O
APRT O
) O
in O
HPRT B
- I
deficient I
mice O
has O
produced O
the O
suggestion O
that O
deficiency B
of I
APRT I
in O
combination O
with O
HPRT B
- I
deficiency I
in O
mice O
may O
lead O
to O
self O
- O
mutilation O
behavior O
[ O
C O
. O
L O
. O
Wu O
and O
D O
. O
W O
. O
Melton O
( O
1993 O
) O
Nature O
Genet O
. O
3 O
, O
235 O
- O
240 O
] O
. O

Administration O
of O
drugs O
that O
inhibit O
adenine O
phosphoribosyltransferase O
( O
APRT O
) O
in O
HPRT B
- I
deficient I
mice O
has O
produced O
the O
suggestion O
that O
deficiency B
of I
APRT I
in O
combination O
with O
HPRT B
- I
deficiency I
in O
mice O
may O
lead O
to O
self O
- O
mutilation O
behavior O
[ O
C O
. O
L O
. O
Wu O
and O
D O
. O
W O
. O
Melton O
( O
1993 O
) O
Nature O
Genet O
. O
3 O
, O
235 O
- O
240 O
] O
. O

Pleiotropic O
defects O
in O
ataxia B
- I
telangiectasia I
protein O
- O
deficient O
mice O
. O

We O
have O
generated O
a O
mouse O
model O
for O
ataxia B
- I
telangiectasia I
by O
using O
gene O
targeting O
to O
generate O
mice O
that O
do O
not O
express O
the O
Atm O
protein O
. O

Atm O
- O
deficient O
mice O
then O
exhibit O
many O
of O
the O
same O
symptoms O
found O
in O
ataxia B
- I
telangiectasia I
patients O
and O
in O
cells O
derived O
from O
them O
. O

In O
patients O
with O
stage B
III I
disease I
, O
the O
respective O
survival O
rates O
were O
59 O
. O

In O
stage B
II I
colorectal I
carcinomas I
, O
the O
absence O
of O
DCC O
identifies O
a O
subgroup O
of O
patients O
with O
lesions O
that O
behave O
like O
stage B
III I
cancers I
. O

Phenotypic O
and O
genotypic O
overlap O
between O
atelosteogenesis B
type I
2 I
and O
diastrophic B
dysplasia I
. O

Mutations O
in O
the O
diastrophic B
dysplasia I
sulfate O
transporter O
gene O
DTDST O
have O
been O
associated O
with O
a O
family O
of O
chondrodysplasias B
that O
comprises O
, O
in O
order O
of O
increasing O
severity O
, O
diastrophic B
dysplasia I
( O
DTD B
) O
, O
atelosteogenesis B
type I
2 I
( O
AO2 B
) O
, O
and O
achondrogenesis B
type I
1B I
( O
ACG1B B
) O
. O

Mutations O
in O
the O
diastrophic B
dysplasia I
sulfate O
transporter O
gene O
DTDST O
have O
been O
associated O
with O
a O
family O
of O
chondrodysplasias B
that O
comprises O
, O
in O
order O
of O
increasing O
severity O
, O
diastrophic B
dysplasia I
( O
DTD B
) O
, O
atelosteogenesis B
type I
2 I
( O
AO2 B
) O
, O
and O
achondrogenesis B
type I
1B I
( O
ACG1B B
) O
. O

To O
learn O
more O
about O
the O
molecular O
basis O
of O
DTDST B
chondrodysplasias I
and O
about O
genotype O
- O
phenotype O
correlations O
, O
we O
studied O
fibroblast O
cultures O
of O
three O
new O
patients O
one O
with O
AO B
- I
2 I
, O
one O
with O
DTD B
, O
and O
one O
with O
an O
intermediate O
phenotype O
( O
AO2 B
/ O
DTD B
) O
. O

Germline O
mutations O
in O
the O
3 O
' O
part O
of O
APC B
exon O
15 O
do O
not O
result O
in O
truncated O
proteins O
and O
are O
associated O
with O
attenuated O
adenomatous B
polyposis I
coli I
. O

Familial B
adenomatous I
polyposis I
( O
FAP B
) O
is O
an O
inherited O
predisposition O
to O
colorectal B
cancer I
characterized O
by O
the O
development O
of O
numerous O
adenomatous B
polyps I
predominantly O
in O
the O
colorectal O
region O
. O

Germline O
mutations O
in O
the O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
are O
responsible O
for O
most O
cases O
of O
FAP B
. O

Autosomal O
dominant O
primary O
hyperparathyroidism B
and I
jaw I
tumor I
syndrome I
associated O
with O
renal B
hamartomas I
and O
cystic B
kidney I
disease I
: O
linkage O
to O
1q21 O
- O
q32 O
and O
loss O
of O
the O
wild O
type O
allele O
in O
renal B
hamartomas I
. O

Hereditary B
hyperparathyroidism I
- I
jaw I
tumor I
syndrome I
( O
HPT B
- I
JT I
) O
is O
an O
autosomal B
dominant I
disease I
( O
OMIM O
145001 O
) O
that O
has O
recently O
been O
mapped O
to O
chromosomal O
region O
1q21 O
- O
q32 O
( O
HRPT2 O
) O
. O

Hereditary B
hyperparathyroidism I
- I
jaw I
tumor I
syndrome I
( O
HPT B
- I
JT I
) O
is O
an O
autosomal B
dominant I
disease I
( O
OMIM O
145001 O
) O
that O
has O
recently O
been O
mapped O
to O
chromosomal O
region O
1q21 O
- O
q32 O
( O
HRPT2 O
) O
. O

Here O
we O
report O
two O
families O
with O
HPT B
- I
JT I
syndrome I
in O
which O
adult B
renal I
hamartomas I
or O
cystic B
kidney I
disease I
were O
prominent O
associated O
features O
, O
possibly O
representing O
a O
new O
phenotypic O
variant O
of O
the O
HPT B
- I
JT I
syndrome I
. O

Here O
we O
report O
two O
families O
with O
HPT B
- I
JT I
syndrome I
in O
which O
adult B
renal I
hamartomas I
or O
cystic B
kidney I
disease I
were O
prominent O
associated O
features O
, O
possibly O
representing O
a O
new O
phenotypic O
variant O
of O
the O
HPT B
- I
JT I
syndrome I
. O

In O
the O
second O
family O
, O
JT B
was O
found O
in O
three O
of O
the O
five O
affected O
individuals O
and O
two O
affected O
members O
also O
exhibited O
polycystic B
kidney I
disease I
. O

Ataxia B
- I
telangiectasia I
: O
founder O
effect O
among O
north O
African O
Jews O
. O

The O
ATM O
gene O
is O
responsible O
for O
the O
autosomal B
recessive I
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
, O
characterized O
by O
cerebellar B
degeneration I
, O
immunodeficiency B
and O
cancer B
predisposition I
. O

The O
ATM O
gene O
is O
responsible O
for O
the O
autosomal B
recessive I
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
, O
characterized O
by O
cerebellar B
degeneration I
, O
immunodeficiency B
and O
cancer B
predisposition I
. O

The O
ATM O
gene O
is O
responsible O
for O
the O
autosomal B
recessive I
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
, O
characterized O
by O
cerebellar B
degeneration I
, O
immunodeficiency B
and O
cancer B
predisposition I
. O

A B
- I
T I
carriers O
were O
reported O
to O
be O
moderately O
cancer B
- I
prone I
. O

A B
- I
T I
carriers O
were O
reported O
to O
be O
moderately O
cancer B
- I
prone I
. O

A O
wide O
variety O
of O
A B
- I
T I
mutations O
, O
most O
of O
which O
are O
unique O
to O
single O
families O
, O
were O
identified O
in O
various O
ethnic O
groups O
, O
precluding O
carrier O
screening O
with O
mutation O
- O
specific O
assays O
. O

However O
, O
a O
single O
mutation O
was O
observed O
in O
32 O
/ O
33 O
defective O
ATM O
alleles O
in O
Jewish O
A B
- I
T I
families O
of O
North O
African O
origin O
, O
coming O
from O
various O
regions O
of O
Morocco O
and O
Tunisia O
. O

This O
founder O
effect O
provides O
a O
unique O
opportunity O
for O
population O
- O
based O
screening O
for O
A B
- I
T I
carriers O
in O
a O
large O
Jewish O
community O
. O
. O

Mutation O
analysis O
of O
BRCA1 O
and O
BRCA2 O
in O
a O
male B
breast I
cancer I
population O
. O

A O
population O
- O
based O
series O
of O
54 O
male B
breast I
cancer I
cases O
from O
Southern O
California O
were O
analyzed O
for O
germ O
- O
line O
mutations O
in O
the O
inherited B
breast I
/ I
ovarian I
cancer I
genes O
, O
BRCA1 O
and O
BRCA2 O
. O

Two O
male B
breast I
cancer I
patients O
( O
4 O
% O
of O
the O
total O
) O
were O
found O
to O
carry O
novel O
truncating O
mutations O
in O
the O
BRCA2 O
gene O
. O

Only O
one O
of O
the O
two O
male B
breast I
cancer I
patients O
carrying O
a O
BRCA2 O
mutation O
had O
a O
family O
history O
of O
cancer B
, O
with O
one O
case O
of O
ovarian B
cancer I
in O
a O
first O
- O
degree O
relative O
. O

The O
remaining O
eight O
cases O
( O
89 O
% O
) O
of O
male B
breast I
cancer I
with O
a O
family O
history O
of O
breast B
/ I
ovarian I
cancer I
in O
first O
- O
degree O
relatives O
remain O
unaccounted O
for O
by O
mutations O
in O
either O
the O
BRCA1 O
gene O
or O
the O
BRCA2 O
gene O
. O
. O

Missense O
mutations O
in O
the O
Fas O
gene O
resulting O
in O
autoimmune B
lymphoproliferative I
syndrome I
: O
a O
molecular O
and O
immunological O
analysis O
. O

The O
Fas O
/ O
Apo O
- O
1 O
receptor O
plays O
a O
crucial O
role O
in O
the O
regulation O
of O
apoptosis O
, O
as O
demonstrated O
by O
lymphoproliferation O
in O
MRL O
- O
lpr O
/ O
lpr O
mice O
and O
by O
the O
recently O
described O
autoimmune B
lymphoproliferative I
syndrome I
( O
ALPS B
) O
in O
humans O
, O
both O
of O
which O
are O
due O
to O
mutations O
in O
the O
Fas O
gene O
. O

The O
ataxia B
- I
telangiectasia I
gene O
product O
, O
a O
constitutively O
expressed O
nuclear O
protein O
that O
is O
not O
up O
- O
regulated O
following O
genome O
damage O
. O

The O
product O
of O
the O
ataxia B
- I
telangiectasia I
gene O
( O
ATM O
) O
was O
identified O
by O
using O
an O
antiserum O
developed O
to O
a O
peptide O
corresponding O
to O
the O
deduced O
amino O
acid O
sequence O
. O

Truncated O
ATM O
protein O
was O
not O
detected O
in O
lymphoblasts O
from O
ataxia B
- I
telangiectasia I
patients O
homozygous O
for O
mutations O
leading O
to O
premature O
protein O
termination O
. O

We O
report O
about O
Dr O
. O
Kniest O
, O
who O
first O
described O
the O
condition O
in O
1952 O
, O
and O
his O
patient O
, O
who O
, O
at O
the O
age O
of O
50 O
years O
is O
severely B
handicapped I
with O
short B
stature I
, O
restricted B
joint I
mobility I
, O
and O
blindness B
but O
is O
mentally O
alert O
and O
leads O
an O
active O
life O
. O

The O
Schwartz B
- I
Jampel I
syndrome I
( O
SJS B
; O
chondrodystrophic B
myotonia I
; O
McK O
255 O
, O
800 O
) O
is O
a O
recessively B
inherited I
condition I
defined O
by O
myotonia B
, O
short B
stature I
, O
and O
bone B
dysplasia I
. O

We O
tentatively O
isolate O
three O
different O
types O
of O
SJS B
type I
1A I
, O
usually O
recognized O
in O
childhood O
, O
with O
moderate O
bone B
dysplasia I
, O
corresponding O
to O
the O
original O
descriptions O
of O
Schwartz O
, O
Jampel O
and O
Aberfeld O
; O
type O
1B O
, O
similar O
to O
type O
1A O
but O
recognizable O
at O
birth O
, O
with O
more O
pronounced O
bone B
dysplasia I
resembling O
Kniest B
dysplasia I
; O
and O
type O
2 O
, O
manifest O
at O
birth O
, O
with O
increased O
mortality O
and O
bone B
dysplasia I
resembling O
Pyle B
disease I
. O

Genetic O
analysis O
of O
the O
family O
with O
two O
sibs O
affected O
by O
SJS B
type I
2 I
showed O
evidence O
against O
linkage O
to O
chromosome O
1p36 O
- O
34 O
. O

While O
only O
5 O
% O
of O
sporadic B
Wilms I
tumours I
have O
intragenic O
WT1 O
mutations O
, O
> O
90 O
% O
of O
patients O
with O
the O
Denys B
- I
Drash I
syndrome I
( O
renal B
nephropathy I
, O
gonadal B
anomaly I
, O
predisposition B
to I
WT I
) O
carry O
constitutional O
intragenic O
WT1 O
mutations O
. O

While O
only O
5 O
% O
of O
sporadic B
Wilms I
tumours I
have O
intragenic O
WT1 O
mutations O
, O
> O
90 O
% O
of O
patients O
with O
the O
Denys B
- I
Drash I
syndrome I
( O
renal B
nephropathy I
, O
gonadal B
anomaly I
, O
predisposition B
to I
WT I
) O
carry O
constitutional O
intragenic O
WT1 O
mutations O
. O

WT1 O
mutations O
have O
also O
been O
reported O
in O
juvenile B
granulosa I
cell I
tumour I
, O
non B
- I
asbestos I
related I
mesothelioma I
, O
desmoplastic B
small I
round I
cell I
tumour I
and O
, O
most O
recently O
, O
acute B
myeloid I
leukemia I
. O
. O

We O
studied O
a O
previously O
described O
Swiss O
family O
with O
inherited B
C9 I
deficiency I
. O

Difficulties O
in O
the O
ascertainment O
of O
C9 B
deficiency I
: O
lessons O
to O
be O
drawn O
from O
a O
compound O
heterozygote O
C9 B
- I
deficient I
subject O
. O

The O
Israeli O
C7 B
- I
deficient I
cases O
all O
share O
a O
C7 O
haplotype O
and O
are O
homozygous O
for O
a O
mis O
- O
sense O
mutation O
in O
exon O
9 O
. O

Isolation O
of O
full O
- O
length O
ATM O
cDNA O
and O
correction O
of O
the O
ataxia B
- I
telangiectasia I
cellular O
phenotype O
. O

A O
gene O
mutated O
in O
the O
human O
genetic B
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
, O
ATM O
, O
was O
recently O
identified O
by O
positional O
cloning O
. O

A O
gene O
mutated O
in O
the O
human O
genetic B
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
, O
ATM O
, O
was O
recently O
identified O
by O
positional O
cloning O
. O

We O
describe O
herein O
, O
to O
our O
knowledge O
, O
for O
the O
first O
time O
, O
the O
cloning O
of O
a O
full O
- O
length O
cDNA O
for O
ATM O
and O
correction O
of O
multiple O
aspects O
of O
the O
radio O
- O
sensitive O
phenotype O
of O
A B
- I
T I
cells O
by O
transfection O
with O
this O
cDNA O
. O

Overexpression O
of O
ATM O
cDNA O
in O
A B
- I
T I
cells O
enhanced O
the O
survival O
of O
these O
cells O
in O
response O
to O
radiation O
exposure O
, O
decreased O
radiation O
- O
induced O
chromosome O
aberrations O
, O
reduced O
radio O
- O
resistant O
DNA O
synthesis O
, O
and O
partially O
corrected O
defective O
cell O
cycle O
checkpoints O
and O
induction O
of O
stress O
- O
activated O
protein O
kinase O
. O

This O
correction O
of O
the O
defects O
in O
A B
- I
T I
cells O
provides O
further O
evidence O
of O
the O
multiplicity O
of O
effector O
functions O
of O
the O
ATM O
protein O
and O
suggests O
possible O
approaches O
to O
gene O
therapy O
. O
. O

atm O
and O
p53 O
cooperate O
in O
apoptosis O
and O
suppression O
of O
tumorigenesis O
, O
but O
not O
in O
resistance O
to O
acute B
radiation I
toxicity I
. O

Mutations O
in O
atm O
and O
p53 O
cause O
the O
human O
cancer B
- I
associated I
diseases I
ataxia B
- I
telangiectasia I
and O
Li B
- I
Fraumeni I
syndrome I
, O
respectively O
. O

Finally O
- O
and O
in O
contrast O
to O
prior O
predictions O
- O
atm O
and O
p53 O
do O
not O
appear O
to O
interact O
in O
acute B
radiation I
toxicity I
, O
suggesting O
a O
separate O
atm O
effector O
pathway O
for O
this O
DNA O
damage O
response O
and O
having O
implications O
for O
the O
prognosis O
and O
treatment O
of O
human O
tumours B
. O
. O

We O
examined O
galactosylceramidase O
( O
GALC O
) O
cDNA O
in O
four O
Japanese O
patients O
with O
adult B
onset I
globoid I
cell I
leukodystrophy I
( O
Krabbe B
disease I
; O
AO B
- I
GLD I
) O
by O
polymerase O
chain O
reaction O
/ O
single O
- O
strand O
conformation O
polymorphism O
( O
PCR O
- O
SSCP O
) O
analysis O
, O
subsequent O
sequence O
determination O
, O
and O
restriction O
enzyme O
digestion O
of O
PCR O
products O
, O
initial O
symptoms O
were O
the O
onset O
of O
slowly O
progressive O
spastic B
paraplegia I
from O
the O
middle O
of O
the O
second O
decade O
, O
and O
all O
patients O
had O
diminished B
GALC I
activity I
in O
their O
leukocytes O
. O

We O
examined O
galactosylceramidase O
( O
GALC O
) O
cDNA O
in O
four O
Japanese O
patients O
with O
adult B
onset I
globoid I
cell I
leukodystrophy I
( O
Krabbe B
disease I
; O
AO B
- I
GLD I
) O
by O
polymerase O
chain O
reaction O
/ O
single O
- O
strand O
conformation O
polymorphism O
( O
PCR O
- O
SSCP O
) O
analysis O
, O
subsequent O
sequence O
determination O
, O
and O
restriction O
enzyme O
digestion O
of O
PCR O
products O
, O
initial O
symptoms O
were O
the O
onset O
of O
slowly O
progressive O
spastic B
paraplegia I
from O
the O
middle O
of O
the O
second O
decade O
, O
and O
all O
patients O
had O
diminished B
GALC I
activity I
in O
their O
leukocytes O
. O

Three O
mutations O
, O
viz O
. O
, O
G270D O
, O
L618S O
, O
and O
exon O
- O
6 O
skipping O
( O
535 O
- O
573del O
) O
, O
produced O
diminished B
GALC I
activity I
as O
expected O
. O

AO B
- I
GLD I
mutations O
, O
including O
those O
found O
here O
, O
are O
located O
in O
the O
N O
- O
terminus O
( O
I66M O
, O
G270D O
, O
535 O
- O
573del O
) O
or O
C O
- O
terminus O
( O
L618S O
) O
of O
the O
GALC O
enzyme O
, O
whereas O
the O
reported O
mutations O
in O
the O
infantile O
form O
( O
IF B
- I
GLD I
) O
are O
in O
the O
central O
domain O
. O

AO B
- I
GLD I
mutations O
, O
including O
those O
found O
here O
, O
are O
located O
in O
the O
N O
- O
terminus O
( O
I66M O
, O
G270D O
, O
535 O
- O
573del O
) O
or O
C O
- O
terminus O
( O
L618S O
) O
of O
the O
GALC O
enzyme O
, O
whereas O
the O
reported O
mutations O
in O
the O
infantile O
form O
( O
IF B
- I
GLD I
) O
are O
in O
the O
central O
domain O
. O

